Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing ...
Moderna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks ...
Moderna Inc.’s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said ...
The US Food and Drug Administration announced Friday that it had advised the makers of the Covid-19 vaccines to formulate ...
The jury found that AstraZeneca's Tagrisso violated Pfizer's Wyeth unit's patent rights under US patents 10,603,314 and ...
Synopsys VC Verification IP (VIP) for Fibre Channel is designed to thoroughly verify Fibre Channel designs using both random and directed simulation. The Fibre Channel VIP provides full protocol ...
Synthesia's new technology is impressive but raises big questions about a world where we increasingly can’t tell what’s real. The FDA is poised to approve the notorious party drug as a therapy. Here’s ...
Drug manufactures Moderna, Pfizer and Novavax said they expect the new vaccines will be available this fall in time for flu ...
Manufacturing is underway and doses of Moderna’s Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval ...
Moderna (MRNA) stock gains as the U.S. is close to fund a late-stage trial for the company's messenger-RNA-based ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board. The company did not provide details on the possible ...